These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30609392)

  • 1. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
    Tray N; Taff J; Singh B; Suh J; Ngo N; Kwa M; Troxel AB; Chae YK; Kurzrock R; Patel SP; Sharon E; Denkert C; Ross JS; Adams S
    Breast; 2019 Apr; 44():29-32. PubMed ID: 30609392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
    Joneja U; Vranic S; Swensen J; Feldman R; Chen W; Kimbrough J; Xiao N; Reddy S; Palazzo J; Gatalica Z
    J Clin Pathol; 2017 Mar; 70(3):255-259. PubMed ID: 27531819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
    BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
    Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
    Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
    Krings G; Chen YY
    Mod Pathol; 2018 Nov; 31(11):1661-1674. PubMed ID: 29946183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
    Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
    Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic landscape of metaplastic breast cancer.
    Tray N; Taff J; Adams S
    Cancer Treat Rev; 2019 Sep; 79():101888. PubMed ID: 31491663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
    Afkhami M; Schmolze D; Yost SE; Frankel PH; Dagis A; Amanam IU; Telatar M; Nguyen K; Yu KW; Luu T; Pillai R; Aoun PA; Mortimer J; Yuan Y
    PLoS One; 2019; 14(11):e0224726. PubMed ID: 31693690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    McQuerry JA; Jenkins DF; Yost SE; Zhang Y; Schmolze D; Johnson WE; Yuan Y; Bild AH
    BMC Cancer; 2019 Sep; 19(1):881. PubMed ID: 31488082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].
    Weigelt B; Ng CK; Shen R; Popova T; Schizas M; Natrajan R; Mariani O; Stern MH; Norton L; Vincent-Salomon A; Reis-Filho JS
    Mod Pathol; 2015 Mar; 28(3):340-51. PubMed ID: 25412848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
    Yam C; Abuhadra N; Sun R; Adrada BE; Ding QQ; White JB; Ravenberg EE; Clayborn AR; Valero V; Tripathy D; Damodaran S; Arun BK; Litton JK; Ueno NT; Murthy RK; Lim B; Baez L; Li X; Buzdar AU; Hortobagyi GN; Thompson AM; Mittendorf EA; Rauch GM; Candelaria RP; Huo L; Moulder SL; Chang JT
    Clin Cancer Res; 2022 Jul; 28(13):2878-2889. PubMed ID: 35507014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New triple-negative breast cancer risk genes identified.
    Gourd E
    Lancet Oncol; 2018 Sep; 19(9):e445. PubMed ID: 30122618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.